Sanofi steps off the sidelines to ink 3 ADC deal with Seagen, reigniting long-held interest in the modality FDA's gene editing guidance is 'par for the course' but still important, analysts say 'Biotech sisterhood': 25 female CEOs find new ways to 'sponsor' the next generation at Arizona retreat Biogen jettisons AMD drug, providing Catalyst for ex-partner's hunt for strategic alternatives With clinical holds lifted, Aprea embarks on 'show me' year for key cancer candidate With $987M round, Frazier looks to form several new biotechs this year, bankroll others Belgian biotech Precirix snags $88M to bankroll radiopharmaceuticals in HER2-positive cancers Ovid finds new focus in epilepsy but trims staff to extend cash runway Zai Lab hires ex-Lilly CFO who departed after investigation found 'inappropriate' behavior In rare flop, Merck calls it quits on Keytruda-Lynparza combo in prostate cancer J&J's DePuy Synthes found guilty of infringing orthopedic device patent in $20M verdict After trial flop, Exelixis drops plan to pair Cabometyx with Roche's Tecentriq in early-stage liver cancer Doctor groups press lawmakers to ignore MedPAC recommendation to stand pat on pay in 2023 It's #FierceMadness: Zepzelca kicks Lumakras, Enspryng tops Vyvgart—and it's over to you for the big vote Featured Story | By Nick Paul Taylor Sanofi is stepping up its long-held interest in antibody-drug conjugates (ADC). Having first teamed up with Immunogen almost 20 years ago, Sanofi has now joined forces with Seagen to jointly fund and develop three anti-cancer ADCs. read more |
| |
|---|
|
Top Stories By Annalee Armstrong “Par for the course.” “Benign.” “Not surprising.” These are some of the creative ways analysts described the FDA’s new guidance on gene editing for biotechs, but they are at least happy to see the FDA take some leadership and provide guidance to industry. read more By Kyle LaHucik Two dozen female CEOs from across the biotech industry came together for a first-of-its-kind retreat this past weekend to network, bounce ideas off one another and form the basis for annual and regional events meant to support women in the C-suite. read more By Nick Paul Taylor Biogen has dumped the dry age-related macular degeneration candidate it licensed from Catalyst Biosciences, giving its onetime partner full control of another asset as it weighs up strategic alternatives. read more By Kyle LaHucik Aprea Therapeutics will test its once-failed lead drug, eprenetapopt, in new clinical trials across various myeloid and lymphoid malignancies after the FDA lifted clinical holds in the past few months. read more By Kyle LaHucik Frazier raised its 11th fund at $987 million to form at least four new biotechs in the next 12 months, bankroll other early-stage startups and continue its 30-year streak of investing in the industry. The investment shop wants to continue investing in small molecules, oncology and dig deeper into China. read more By Kyle LaHucik Precirix secured nearly $88 million to bankroll an ongoing phase 1/2 study of its lead radiopharmaceutical in patients with certain breast and gastric cancers. The Belgian biotech also plans to enter a second molecule into the clinic next year and another thereafter as it expands its operations into the U.S. read more By Max Bayer Ovid Therapeutics seems to have found its focus after a rough year: epilepsy. But the biotech will move toward this new direction with 20% fewer people at the company. read more By Kyle LaHucik Zai Lab has hired ex-Eli Lilly finance chief Josh Smiley, who exited the Big Pharma last year after an external investigation found he had "poor judgment" and exhibited "inappropriate" behavior with multiple coworkers. read more By Angus Liu The combination of two powerful drugs with excellent clinical track records isn’t necessarily a guarantee for success. Merck just found out that a pairing of Keytruda and Lynparza didn't work in some prostate cancer patients. read more By Andrea Park Gary Lynn Rasmussen, M.D., accused DePuy of having used two of his patented inventions “without his permission or compensation.” His mechanisms were allegedly integrated into DePuy’s Attune system for knee replacement procedures. read more By Fraiser Kansteiner After last year’s surprise flop in previously untreated hepatocellular carcinoma (HCC)—the most common type of liver cancer—Exelixis’ hopes dimmed around the combination of its tyrosine kinase inhibitor Cabometyx with Roche’s immuno-oncology agent Tecentriq. Now, the other shoe has dropped. read more By Robert King Doctor groups are urging lawmakers to ignore recommendations from MedPAC that they freeze any pay increase to practices for 2023. read more By Ben Adams It’s March, so it’s time for some #FierceMadness. We’re looking for the best of the best in drug names—and with Jazz' Zepzelca, Roche's Enspryng, AbbVie's Qulipta and Novartis' Leqvio advancing from the play-in round, we have our full bracket for your voting pleasure. read more Resources Sponsored by: H1 Read why many MSLs are still challenged in developing integrated strategies to increase the volume of meaningful engagements. Download this industry report to find out what the top challenges are and suggestion strategies to solve them. Download now. Sponsored by: Medidata, a Dassault Systèmes company The landscape of clinical trials has been permanently changed. Today's trials require sponsors to modernize their use of technology and data to adapt. This eBook provides an overview of how sponsors can empower trials with real-time performance data to improve study integrity, reduce risks, optimize patient safety, and increase trial success rates. Sponsored by: Thermo Fisher Scientific Learn how to navigate the top manufacturing challenges and achieve a seamless transition from discovery to clinical manufacturing across the CAR T-cell therapy workflow. Sponsored by: Oracle Health Sciences Learn about ways to break down regulatory roadblocks and get closer to 100% clarity on regulatory positions to advance decentralized clinical trials in research. Sponsored by: Oracle Health Sciences How to overcome top challenges faced in decentralized trials. Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Fierce BD&L Summit for Life Sciences March 15-16, 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Pharma PR & Communications Summit West June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce MedTech Summit August 8-9, 2022 | Minneapolis, MN Promotional Review Committee Compliance and Best Practices Summit West (PRC West) September 2022 | San Diego, CA Medical Affairs Strategic Summit (MASS West) September 2022 | San Diego, CA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 